Managing AL and ATTR Amyloidosis

CE / CME

Advances in Systemic Amyloidosis: A Spotlight on New Disease-Modifying Therapies Across the Clinical Spectrum

Pharmacists: 1.25 contact hours (0.125 CEUs)

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Nurses: 1.25 Nursing contact hours

Released: October 21, 2021

Expiration: October 20, 2022

Activity

Progress
1
Course Completed

In this module developed for the multidisciplinary care team, Shaji K. Kumar, MD, reviews key data and guidance on optimal management of amyloid light-chain (AL) and amyloid transthyretin (ATTR) amyloidosis, from diagnosis and risk stratification to current and emerging therapeutic strategies. Beth Faiman, PhD, MSN, APRN-BC, AOCN, provides multidisciplinary supportive care considerations for patients with AL and ATTR amyloidosis.

The key points discussed in this module are illustrated with thumbnails from an accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in this module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with amyloidosis do you provide care for in a typical month?

Which of the following tests is needed for the accurate typing of amyloid protein to guide the clinical management of patients with systemic amyloidosis?

Which of the following signs or symptoms is more commonly associated with AL amyloidosis than ATTR amyloidosis?

A 62-year-old man with newly diagnosed AL is referred to your office for care. The patient’s kidney biopsy is positive for amyloidosis via Congo red staining, and immunohistochemical staining shows λ κ predominance. The patient was an avid runner and works full time. His estimated glomerular filtration rate (eGFR) is 35 mL/min.

In your practice, which of the following regimens would you recommend for this patient?

Which of the following FDA-approved therapy options would be most appropriate for a patient presenting with newly diagnosed acquired ATTR amyloidosis and symptoms indicating cardiomyopathy?